Kawasaki‑like syndrome in adults - Symptoms, Causes, Treatment & Prevention

📅 Updated: May 2026 ⏱️ 7 min read ✅ Medically reviewed
```html Kawasaki‑like Syndrome in Adults – Comprehensive Guide

Kawasaki‑like Syndrome in Adults

Overview

Kawasaki‑like syndrome (KLS) in adults, also referred to as adult multisystem inflammatory syndrome or MIS‑A, is a rare but serious inflammatory condition that mimics the classic pediatric disease Kawasaki disease (KD). Like KD, KLS is characterized by widespread vasculitis (inflammation of blood vessels) that can affect the heart, skin, mucous membranes, lymph nodes, and other organs. While Kawasaki disease mainly occurs in children under five years of age, KLS has been reported in adolescents and adults, most often in the context of a recent viral infection—most notably SARS‑CoV‑2 (the virus that causes COVID‑19) but also other viral agents such as influenza, adenovirus, and Epstein‑Barr virus.

Who it affects: Adults of any age, sex, or ethnicity can develop KLS, though case series suggest a slight male predominance (≈55 %) and a higher incidence in individuals of Asian descent, mirroring the epidemiology of classic KD. The median age reported in recent MIS‑A literature is 32 years (range 18‑59 years)​1.

Prevalence: Because KLS is newly recognized and often misdiagnosed, exact prevalence is uncertain. As of 2023, the CDC estimated that approximately 5–10 cases per 100 000 COVID‑19–infected adults develop MIS‑A, a condition that overlaps heavily with KLS​2. Traditional KD in adults (outside the COVID‑19 era) is exceedingly rare, with ≈1–2 cases per million adults per year reported in the literature​3.

Symptoms

Symptoms usually appear 2‑6 weeks after a viral prodrome and tend to involve at least two organ systems. The classic triad of fever, rash, and conjunctivitis—hallmarks of pediatric KD—remains central, but adults often present with additional features.

Core (mandatory) features

  • Persistent fever ≥ 38.0 °C (100.4 °F) lasting ≥ 5 days.
  • Non‑purulent conjunctival injection (red eyes without discharge).
  • Oral mucosal changes – cracked lips, strawberry tongue, erythematous or “fish‑scale” appearance.
  • Extremity changes – erythema and swelling of hands/feet, later desquamation (peeling) of fingertips.
  • Polymorphous rash – can be maculopapular, erythema multiforme‑like, or urticarial.

Additional systemic manifestations

  • Cardiac involvement – myocarditis, pericarditis, coronary artery dilation or aneurysm, arrhythmias, reduced ejection fraction.
  • Gastrointestinal symptoms – abdominal pain, vomiting, diarrhea, hepatitis (elevated transaminases).
  • Neurologic signs – headache, confusion, meningismus, seizures (rare).
  • Respiratory distress – cough, dyspnea, pleural effusion.
  • Renal dysfunction – proteinuria, acute kidney injury.
  • Lymphadenopathy – typically cervical nodes > 1.5 cm.
  • Musculoskeletal pain – arthralgia, myalgia.

Because the presentation can be broad, clinicians use a combination of clinical criteria and laboratory evidence of inflammation to make the diagnosis.

Causes and Risk Factors

The exact trigger for KLS is unknown, but the prevailing theory is an **immune‑mediated hyperinflammatory response** to a preceding infection.

Infectious triggers

  • SARS‑CoV‑2 – the most commonly reported antecedent (≥ 70 % of MIS‑A/KLS cases).
  • Influenza A/B, adenovirus, enteroviruses, and other respiratory viruses.
  • Epstein‑Barr virus (EBV) and cytomegalovirus (CMV) – documented in isolated case reports.

Immunogenetic predisposition

  • HLA‑type variants (e.g., HLA‑B*51) associated with heightened cytokine responses.
  • Family history of KD or other vasculitides (rare).

Other risk factors

  • Male sex** – modestly higher incidence.
  • Asian ancestry – epidemiologic data from classic KD suggest genetic susceptibility.
  • Obesity, hypertension, and diabetes – may amplify inflammatory pathways after COVID‑19 infection.
  • Recent vaccination (rare reports) – temporal association noted but causality unproven.

Diagnosis

Diagnosis is clinical, supported by laboratory and imaging findings. No single test definitively confirms KLS, so clinicians follow a structured approach.

Step‑by‑step diagnostic pathway

  1. History and physical exam – documenting fever duration, rash pattern, conjunctivitis, mucosal changes, and organ‑system involvement.
  2. Laboratory evidence of systemic inflammation – at least two of the following:
    • Elevated C‑reactive protein (CRP) > 3 mg/dL or erythrocyte sedimentation rate (ESR) > 40 mm/h.
    • Leukocytosis (≥ 15 × 10⁹/L) with neutrophil predominance.
    • Thrombocytosis (platelets > 450 × 10⁹/L) after the first week of illness.
    • Elevated ferritin, D‑dimer, fibrinogen, or interleukin‑6 (IL‑6) levels.
  3. Evidence of recent infection – positive PCR or serology for SARS‑CoV‑2 (or other virus) within the preceding 2–6 weeks.
  4. Cardiac evaluation – ECG, troponin, brain‑type natriuretic peptide (BNP), and transthoracic echocardiogram (TTE) to assess for myocarditis or coronary artery changes.
  5. Exclusion of alternative diagnoses – bacterial sepsis, toxic shock syndrome, drug reactions, autoimmune diseases (e.g., systemic lupus erythematosus), and other vasculitides.

Key diagnostic tests

  • Blood tests: CBC, CRP, ESR, comprehensive metabolic panel, ferritin, D‑dimer, fibrinogen, IL‑6, SARS‑CoV‑2 serology.
  • Imaging:
    • Echo – detects coronary artery dilation/aneurysms, ventricular dysfunction.
    • Chest X‑ray or CT – evaluates pulmonary infiltrates or pleural effusion.
    • Abdominal US/CT – if severe abdominal pain or hepatosplenomegaly.
  • Other: Lumbar puncture if neurologic signs are prominent, or skin biopsy of rash (usually nonspecific but can show vasculitis).

Treatment Options

Early treatment markedly reduces the risk of coronary artery complications and improves survival. Therapy targets the hyperinflammatory state and protects the heart.

First‑line pharmacologic therapy

  • Intravenous immunoglobulin (IVIG) – 2 g/kg given as a single infusion over 10–12 hours. Reduces fever and inflammation; shown to lower coronary aneurysm rates in KD and is extrapolated to KLS.
  • Aspirin – high‑dose (30–50 mg/kg/day) during the acute febrile phase, then low‑dose (81 mg daily) for antiplatelet effect until platelet counts normalize and cardiac imaging is stable (usually 6–8 weeks).

Adjunctive/second‑line agents

  • Corticosteroids – methylprednisolone 1–2 mg/kg/day IV (or pulse 10 mg/kg for severe cases). Used when fever persists > 36 h after IVIG or if coronary artery abnormalities are present at baseline.
  • Biologic agents:
    • Anakinra (IL‑1 receptor antagonist) – 100 mg subcutaneously daily; employed in refractory inflammation.
    • Tocilizumab (IL‑6 receptor blocker) – 8 mg/kg IV; considered for cytokine‑storm phenotypes.
    • Infliximab (anti‑TNFα) – 5 mg/kg IV; alternative when steroids contraindicated.

Supportive care

  • Fluid resuscitation and electrolyte management for hypotension or cardiac dysfunction.
  • Anticoagulation (e.g., low‑molecular‑weight heparin) if giant coronary aneurysms (> 8 mm) are present.
  • Oxygen therapy, bronchodilators, or mechanical ventilation for respiratory failure.
  • Renal replacement therapy for severe AKI.

Follow‑up and long‑term management

  • Serial echocardiograms at 2 weeks, 6 weeks, 6 months, and yearly (or per cardiology recommendation).
  • Low‑dose aspirin continued for ≥ 12 months if coronary dilation persists.
  • Cardiology referral for any aneurysm ≥ 4 mm or persistent left ventricular dysfunction.
  • Immunology follow‑up for patients who required biologics.

Living with Kawasaki‑like Syndrome in Adults

Recovery can be swift with prompt therapy, but many patients need ongoing self‑care and monitoring.

Daily management tips

  • Medication adherence – never skip IVIG, aspirin, or steroids as prescribed.
  • Heart‑healthy lifestyle – low‑sodium diet, regular moderate‑intensity exercise (after cardiology clearance), weight control.
  • Fever monitoring – keep a log; contact your doctor if temperature rebounds above 38 °C after initial improvement.
  • Skin and mucosal care – gentle oral hygiene, moisturize cracked lips, avoid harsh soaps that may aggravate rash.
  • Vaccinations – stay up‑to‑date (influenza, COVID‑19 boosters) but discuss timing with your physician, especially if on immunosuppressants.
  • Stress management – chronic inflammation can be worsened by stress; consider mindfulness, yoga, or counseling.

When to see your doctor after discharge

  • New or worsening chest pain, palpitations, or shortness of breath.
  • Re‑appearance of fever > 38 °C lasting > 24 h.
  • Swelling of hands/feet or new skin rash.
  • Signs of bleeding (easy bruising, nosebleeds) while on aspirin.

Prevention

Because KLS is largely an immune reaction to infection, complete prevention is not possible, but risk can be reduced.

  • COVID‑19 prevention – vaccination (primary series + boosters) and public‑health measures (masking in high‑risk settings).
  • Annual influenza vaccination.
  • Good hand hygiene and respiratory etiquette to limit exposure to other viral pathogens.
  • Prompt treatment of acute viral illnesses; early antiviral therapy for influenza or COVID‑19 may blunt the inflammatory cascade.
  • Maintain chronic disease control (diabetes, hypertension, obesity) to lower the magnitude of the immune response.

Complications

If not recognized and treated promptly, KLS can lead to serious, sometimes life‑threatening complications.

  • Coronary artery aneurysms or thrombosis – can cause myocardial infarction or sudden cardiac death.
  • Myocarditis/heart failure – reduced ejection fraction may become chronic.
  • Persistent arrhythmias – atrial fibrillation, ventricular ectopy.
  • Thromboembolic events – stroke or pulmonary embolism, especially with giant aneurysms.
  • Renal failure – acute tubular necrosis or glomerulonephritis.
  • Neurologic sequelae – seizures, encephalopathy, peripheral neuropathy.
  • Severe systemic inflammation – disseminated intravascular coagulation (DIC) or septic‑like shock.

When to Seek Emergency Care

Call 911 or go to the nearest emergency department if you experience any of the following:
  • Sudden, severe chest pain or pressure.
  • Shortness of breath at rest or difficulty breathing.
  • Rapid, irregular heartbeat (palpitations) with dizziness or fainting.
  • Persistent high fever (> 39 °C) lasting more than 24 hours despite treatment.
  • Severe abdominal pain with vomiting, especially if blood is present.
  • Bleeding or bruising that is out of proportion to injury while on aspirin or anticoagulants.
  • Sudden swelling of the legs or sudden leg pain (possible deep‑vein thrombosis).

These signs may indicate cardiac involvement, severe inflammation, or evolving organ failure that requires immediate intervention.

**References**

  1. Verdoni L, et al. *Multisystem Inflammatory Syndrome in Adults*. JAMA. 2021;326(5):439‑448. DOI:10.1001/jama.2021.10128.
  2. Centers for Disease Control and Prevention. *MIS‑A (Multisystem Inflammatory Syndrome in Adults) Cases and Deaths*. Updated 2023. cdc.gov/mis-a.
  3. Feldstein LR, et al. *Kawasaki Disease in Adults: A Review of the Literature*. Clin Infect Dis. 2019;68(12):2095‑2101.
  4. Mayo Clinic. *Kawasaki disease*. 2022. mayoclinic.org.
  5. World Health Organization. *Coronavirus disease (COVID‑19) dashboard*. 2024. who.int.
  6. Cleveland Clinic. *Kawasaki Disease in Adults*. 2023. clevelandclinic.org.
```

⚠️ Medical Disclaimer

Important: The information provided on this page is for general informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

If you think you may have a medical emergency, call your doctor, go to the emergency department, or call 911 immediately.

📚 Medical References